CD274 and non-small cell lung carcinoma: Early-phase clinical trials using anti-PD-1 and PD-L1 antibodies have demonstrated favorable objective responses in patients with non-small cell lung cancer, malignant melanoma, and renal cell carcinoma [41–43].